Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar;2(1):48-57.
doi: 10.1212/CPJ.0b013e31824cb09b.

Practice patterns of US neurologists in patients with CIS, RRMS, or RIS: A consensus study

Carlo Tornatore  1 , J Theodore Phillips, Omar Khan, Aaron E Miller, Christopher J Barnes
Affiliations

Practice patterns of US neurologists in patients with CIS, RRMS, or RIS: A consensus study

Carlo Tornatore et al. Neurol Clin Pract. 2012 Mar.

Abstract

We assess current practice patterns of US neurologists in patients with clinically isolated syndrome (CIS), relapsing-remitting multiple sclerosis (RRMS), and radiologically isolated syndrome (RIS) using case-based surveys. For CIS, 87% recommended initiation of disease-modifying therapy (DMT) with MRI brain lesions. An injectable DMT was recommended by 90%-98% for treatment-naive, mild RRMS patients. There was 97% consensus to treat highly active RRMS, but no consensus on therapy choice. With RIS, there was consensus not to initiate treatment with brain but no spinal MRI lesions. Current US treatment patterns emphasize MRI in MS diagnosis and subsequent treatment decisions, treatment of early disease, aggressive initial treatment of highly active MS, and close patient monitoring.

PubMed Disclaimer

References

    1. Smith B, Carson S, Fu R, et al. Drug class review: disease-modifying drugs for multiple sclerosis: final update 1 report [Internet]. In: Drug Class Reviews. Portland, OR: Oregon Health & Science University; 2010 - PubMed
    1. Clegg A, Bryant J. Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness. Expert Opin Pharmacother 2001;2:623–639 - PubMed
    1. Aktas O, Küry P, Kieseier B, Hartung HP. Fingolimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol 2010;6:373–382 - PubMed
    1. TYSABRI (natalizumab) prescribing information (2012). http://www.tysabri.com/en_US/tysb/site/pdfs/TYSABRI-pi.pdf Accessed February 4, 2011
    1. Gold R. Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved. CNS Drugs 2011;25:37–52 - PubMed